Changes in the <font color="red">fatty_1</font> <font color="red">acid_1</font> <font color="red">composition_1</font> <font color="red">of_1</font> <font color="red">the_1</font> <font color="red">plasma_1</font> <font color="red">lipid_1</font> <font color="red">esters_1</font> during lipid - lowering treatment with diet , clofibrate and niceritrol . Reduction of the proportion of <font color="red">linoleate_1</font> by clofibrate but not by niceritrol . 
<br>
<br> The <font color="red">fatty_1</font> <font color="red">acid_1</font> <font color="red">composition_1</font> <font color="red">of_1</font> <font color="red">the_1</font> <font color="red">plasma_1</font> <font color="red">lipid_1</font> <font color="red">esters_1</font> has been studied during lipid - lowering treatment of 95 patients with atherosclerotic disease . During the first two months of the trial only a diet was prescribed . During the ensuing two months either clofibrate or niceritrol , a nicotinic acid ester , was added in a randomized order . During the last two months the second drug was added . The combined treatment with diet , clofibrate and niceritrol caused highly significant <font color="red">serum_1</font> <font color="red">lipid_1</font> <font color="red">reductions_1</font> <font color="red">._1</font> The <font color="red">fatty_1</font> <font color="red">acid_1</font> <font color="red">composition_1</font> <font color="red">in_1</font> <font color="red">the_1</font> <font color="red">plasma_1</font> <font color="red">lipid_1</font> <font color="red">esters_1</font> was determined in samples from each trial period to measure the degree of dietary adherence . During dietary treatment the relative <font color="red">content_1</font> <font color="red">of_1</font> <font color="red">saturated_1</font> <font color="red">and_1</font> <font color="red">monounsaturated_1</font> <font color="red">fatty_1</font> <font color="red">acids_1</font> secreased and the <font color="red">polyunsaturated_1</font> <font color="red">fatty_1</font> <font color="red">acids_1</font> increased with an increasing <font color="red">ratio_1</font> <font color="red">between_1</font> <font color="red">pulyunsaturated_1</font> <font color="red">and_1</font> <font color="red">saturated_1</font> <font color="red">fatty_1</font> <font color="red">acids_1</font> <font color="red">(_1</font> <font color="red">P_1</font> <font color="red">/_1</font> <font color="red">S_1</font> <font color="red">ratio_1</font> <font color="red">)_1</font> <font color="red">in_1</font> <font color="red">the_1</font> <font color="red">cholesterol_1</font> <font color="red">esters_1</font> <font color="red">and_1</font> <font color="red">triglycerides_1</font> <font color="red">._1</font> Only minor changes were seen in the <font color="red">phospholipids_1</font> <font color="red">._1</font> The changes caused by the diet were partly reversed by clofibrate while niceritrol did not cause any major changes of the <font color="red">fatty_1</font> <font color="red">acid_1</font> <font color="red">composition_1</font> <font color="red">._1</font> Clofibrate treatment coincided with increasing amounts of <font color="red">monounsaturated_1</font> <font color="red">fatty_1</font> <font color="red">acids_1</font> <font color="red">,_1</font> especially <font color="red">oleate_1</font> <font color="red">(_1</font> <font color="red">18_1</font> <font color="red">:_1</font> <font color="red">1_1</font> <font color="red">)_1</font> <font color="red">,_1</font> in the cholesterol esters , triglycerides and phospholipids while there were significant reductions of the content of <font color="red">linoleic_1</font> <font color="red">(_1</font> <font color="red">18_1</font> <font color="red">:_1</font> <font color="red">2_1</font> <font color="red">)_1</font> <font color="red">acid_1</font> in both the cholesterol esters and triglycerides . The <font color="red">18_1</font> <font color="red">:_1</font> <font color="red">2/18_1</font> <font color="red">:_1</font> <font color="red">1_1</font> <font color="red">ratio_1</font> decreased significantly in all the lipid esters analyzed . However , the <font color="red">P_1</font> <font color="red">/_1</font> <font color="red">S_1</font> <font color="red">ratio_1</font> was not significantly affected , partly because the relative content of <font color="red">saturated_1</font> <font color="red">fatty_1</font> <font color="red">acids_1</font> also tended to decrease during clofibrate treatment . It is concluded that addition of clofibrate treatment to patients who are on a diet enriched with polyunsaturated fats is associated with a change from <font color="red">polyunsaturated_1</font> <font color="red">to_1</font> <font color="red">monounsaturated_1</font> <font color="red">fatty_1</font> <font color="red">acids_1</font> <font color="red">in_1</font> <font color="red">the_1</font> <font color="red">plasma_1</font> <font color="red">lipid_1</font> <font color="red">esters_1</font> but does not significantly effect the <font color="red">ratio_1</font> <font color="red">between_1</font> <font color="red">polyunsaturated_1</font> <font color="red">and_1</font> <font color="red">saturated_1</font> <font color="red">fatty_1</font> <font color="red">acids_1</font> <font color="red">._1</font> The <font color="red">fatty_1</font> <font color="red">acid_1</font> <font color="red">changes_1</font> caused by clofibrate treatment and counteracted by an increased amount of polyunsaturated fat in the diet .